相关实验视频

Updated: Jan 18, 2026

Generation of Human CD40-activated B cells

Generation of Human CD40-activated B cells

Published on: October 16, 2009

用CD40激动剂功能化的重组蜘蛛丝显示了在体外激活人类B细胞的能力提高 - 一个用于癌症免疫治疗的新型模块

Gunnar Keller¹, Mona Widhe¹, Ronnie Jansson¹

¹Department of Protein Science, Division of Protein Technology, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, AlbaNova University Center, Stockholm, Sweden.

International journal of biological macromolecules

|September 8, 2025

概括

这项研究开发了一种新的蜘蛛丝药物递送平台,用于局部的CD40激活,增强对瘤的免疫反应. 功能化的丝成功刺激了B细胞,显示了改善癌症治疗的潜力.

科学领域:

生物材料科学生物材料科学
免疫学免疫学免疫学
药物输送系统药物输送系统

背景情况:

针对CD40的抗原呈现细胞激活显示出癌症治疗的前景,但面临严重副作用的挑战.
局部CD40激活是一种克服系统方法局限性的策略.

研究的目的:

开发和评估一种基于蜘蛛丝的新型药物递送平台,用于局部CD40激活.
评估丝结合的CD40激动剂的生物活性和免疫调节潜力.

主要方法:

一个针对CD40的单链变量片段 (scFvCD40) 与重组蜘蛛丝结构的酶性合.
在体外评估使用CD40-激素激剂-响应的记者细胞系和人类初级B细胞.
对B细胞激活标记物 (CD86) 和增殖的分析.

主要成果:

这种scFvCD40-丝结构证明了已确认的生物活性.
使用scFvCD40-silk对人类B细胞进行刺激,导致CD86的调节升高3倍,B细胞的增殖增加4倍.
用scFvCD40功能化的丝微球有效地激活了CD40表达细胞.

结论:

新型蜘蛛丝平台可实现局部的CD40激活,潜在地克服系统性副作用.
功能化丝显示出增强抗原呈现能力和引导T细胞对免疫激活的反应的潜力.
丝微球适用于在癌症治疗中提供免疫调节的生物物质.

关键词:

生物制剂生物制剂生物制剂针对CD40的目标设定接收器聚类是指接收器聚类.复合蜘蛛丝蛋白是一种复合蜘蛛丝蛋白.免疫细胞调节,抗原呈现细胞的细胞调节.单链变量碎片单链变量碎片

更多相关视频

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.